top of page
  • Writer's pictureAbacus Research

IQV Update ($127)

One year ago we concluded: "the stock is around fair value, however given the widening moat, the defensiveness of the business, plus the potential for acceleration, it is attractive."

After H1 2018 acceleration in bookings  we see clear evidence that the strategy is working in clinical trials (~50% of profits) and acceleration of revenue is getting closer. We expect next 12-month backlog conversion numbers (disclosed Qtly) to start improving from Q3 (est 1/11/18), providing a catalyst for upward revisions to conservative 2019 and 2020 consensus estimates.

Growth improvement in Technology business over last year has been supported by aggressive M&A, although organic growth remains muted. However, a number of new product introductions and partnerships make us more optimistic. We believe IQV’s Tech business is in the right space at right time with access to customers, positioning it well for future.

The magnitude of the acceleration still remains difficult to predict, but given the increasing evidence of that acceleration, and high quality, with limited downside, we think IQV remains an attractive bet. 

Link to original report and basics on IQV's business. 

Recent Posts

See All

Fortive: potential14% IRR

Fortive is a high quality business with an asset light model, high margins, high incremental margins and consistent FCF generation that is reinvested in M&A. Recent guidance for slow organic growth fo

Vertiv (VRT) - Datacentre play on AI theme

Vertiv is a leader in critical infrastructure for datacentres and a clear beneficiary of AI driven growth. AI tailwind for datacentres is only starting. To date, Vertiv has seen little to no impact fr

Palantir (PLTR)

The advent of LLM’s have changed Palantir's relationships with institutions – the commercial market is now open to what Palantir is selling. This is a significant change from one year ago. AIP bootcam


bottom of page